|

Iberdomide Clinical Trials

17 actively recruiting trials across 12 locations

Also known as: 1323403-33-3, BMS-986382, C25H28N3O5Cl, CC 220, CC-220, CC220, CELMoD, Iberdomide hydrochloride

Other4 trials

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Phase 1/2
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Phase 3
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
Phase 2
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Phase 2

San Francisco, California2 trials

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program

Phase 1
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

University of Calfornia, San Francisco

Phase 1

Birmingham, Alabama1 trial

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

University of Alabama at Birmingham

Phase 1

Phoenix, Arizona1 trial

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

Mayo Clinic Hospital in Arizona

Phase 1

Beverly Hills, California1 trial

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Beverly Hills Cancer Center /ID# 266921

Phase 1

Irvine, California1 trial

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 2

Aurora, Colorado1 trial

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Rocky Mountain Cancer Centers

Phase 3

Washington D.C., District of Columbia1 trial

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

Lombardi Comprehensive Cancer Center

Phase 1/2

Miami, Florida1 trial

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

University of Miami

Phase 2

Atlanta, Georgia1 trial

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Emory University Hospital Midtown

Phase 1

Boston, Massachusetts1 trial

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Brigham and Women's Hospital

Phase 1/2

Detroit, Michigan1 trial

Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

Karmanos Cancer Institute

Phase 2

Rochester, Minnesota1 trial

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Mayo Clinic in Rochester

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.